@KroenkeLab

The Krönke Lab focusses on Hematologic Malignancies at the Department of Hematology and Oncology, Charité – Universitätsmedizin Berlin

 Berlin, Germany
haema-cbf.charite.de
Joined October 2020
  • Tweets19
  • Following145
  • Followers192
Anti-BCMA TCE in newly diagnosed myeloma. New era is here, end of HCT? congrats @RaabMarc @RascheLeo nature.com/articles/s41591-0…

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a...

Nature Medicine - In the ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trial in patients with transplant-eligible, newly diagnosed multiple myeloma, induction with the BCMA×CD3 bispecific...

nature.com
1
24
5
43
15,732
Protein-Genomics Myeloma Session #ASH24 chaired by Dr Paola Neri ⁦@FrancescoMaura4⁩ @kronkelab ⁦@fabianaperna⁩
7
2
26
1,970
Early View | Haematologica haematologica.org/article/vi… Finally first results from our Phase 1 TCR study targeting MAGE-A1 in myeloma! Hopefully more to come in advanced solid tumors where need for innovative (cellular) therapies is still HUGE.
2
6
470
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | NEJM

A woman with aggressive refractory systemic lupus erythematosus was treated with a short course of the bispecific antibody teclistamab (anti–B-cell maturation antigen and anti-CD3) and had a drug-...

nejm.org
4
1
10
1,779
Happy to share that our #proteogenomic study of multiple myeloma led by Evelyn Ramberger is out now @NatureCancer rdcu.be/dL9wZ @MDC_Berlin @ChariteBerlin @berlinnovation
5
6
22
2,096
Wonderful collaboration with Philipp Mertins, Stefan Knop, DSMM study group, and many others!
1
189
Our multiomics analysis including deep TMT-based (phospho)proteomics, RNA sequencing, and nanopore DNA sequencing of 138 primary multiple myeloma samples reveals new insights into disease biology and treatment opportunities
1
198
Krönke Lab retweeted
Mick Milsom@MilsomMick15 May 2024
We had a record number of (high quality) abstracts for this year’s Mol Hem workshop @EHA_Hematology annual meeting. Check out the 12 selected talks ehaweb.org/congress/eha2024-…
1
3
1
47
5,329
Our paper on using heteroPROTACs to induce potent pan-IAP degradation is finally out! Check out our results from the IAP vs VHL&CRBN battle 🥊—> bit.ly/3K0aMCp Very happy about this great collaboration with our established team 😁@IzidorSosic @c_steinebach, @KroenkeLab

Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins

Abstract. Proteolysis targeting chimeras (PROTACs) represent a new pharmacological modality to inactivate disease-causing proteins. PROTACs operate via rec

pubs.acs.org
2
5
2
35
4,128
Krönke Lab retweeted
Haas Lab@haas_lab22 Nov 2022
Excited to announce that our lab has been awarded an #ERC_StG grant to study immunological interactions in leukemias. Thanks to our team members, collaborators, friends and family for the constant support! @berlinnovation @MDC_Berlin @ChariteBerlin @ERC_Research
European Research Council (ERC)
@ERC_Research22 Nov 2022
📢 The ERC's 2022 Starting Grant competition results are now revealed. Over €636 million to fund the best ideas of younger scientists. Find out who, where and why 👉 bit.ly/3JRyDDg 🇪🇺#EUfunded @HorizonEU #FrontierResearch #ERCStG
31
11
2
205
It's the E3 ligase Smac-down!🥊VHL and CRBN face IAPs head to head.🥊Who shall prevail? Welp, our preprint title gives it out, IAPs get totally K.O.'d. bit.ly/3QHGGEV. A great collaboration from @c_steinebach, @KroenkeLab, @AlesaBricelj and @IzidorSosic #TPD #PROTACs

Heterobifunctional Ligase Recruiters Enable Pan-Degradation of Inhibitor of Apoptosis Proteins |...

Proteolysis targeting chimeras (PROTACs) represent a new pharmacological modality to inactivate disease-causing proteins. PROTACs operate via recruiting E3 ubiquitin ligases, which enables the...

chemrxiv.org
3
6
2
48
Very excited to share our latest work, now published online first in @CD_AACR! Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts aacrjournals.org/cancerdisco…
5
9
1
47
We employed the BTB domain of transcription factor BCL6 as small-molecule-controlled reversible oligomerization switch. Led by @lena_nitsch and my first corresponding author manuscript @CellRepMethods 1/16 cell.com/cell-reports-method…
10
25
5
110
Happy to announce our new work identifying cdk6 in lenalidomide resistant multiple myeloma published in @NatureComms rdcu.be/cHA4R great collaboration @ChariteBerlin @MDC_Berlin
6
1
31
Krönke Lab retweeted
Ohad Hammer@ohadhammer29 Oct 2021
First $ARVN, then $KYMR, now $NRIX PROTACS work!!! Not sure this class gets the credit it deserves for its huge potential. Still early days and chemistry isn't trivial but the potential here is huge: The ability to degrade every protein with an oral small molecule...
6
24
6
187
Check our new paper Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…
2
1
14
Load more